TMCnet News

Research and Markets: Aids - Related Lymphoma - Pipeline Review, Q3 2011 Is Built Using Data and Information Sourced from Proprietary Databases
[July 29, 2011]

Research and Markets: Aids - Related Lymphoma - Pipeline Review, Q3 2011 Is Built Using Data and Information Sourced from Proprietary Databases


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/c739eb/aids_related_lym) has announced the addition of Global Markets Direct's new report "Aids - Related Lymphoma - Pipeline Review, Q3 2011" to their offering.

Global Markets Direct's, 'Aids - Related Lymphoma - Pipeline Review, Q3 2011', provides an overview of the Aids - Related Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Aids - Related Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic deelopment for Aids - Related Lymphoma. 'Aids - Related Lymphoma - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

  • A snapshot of the global therapeutic scenario for Aids - Related Lymphoma.
  • A review of the Aids - Related Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Aids - Related Lymphoma pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy


  • Identify and understand important and diverse types of therapeutics under development for Aids - Related Lymphoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Aids - Related Lymphoma pipeline depth and focus of Aids - Related Lymphoma therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/c739eb/aids_related_lym


[ Back To TMCnet.com's Homepage ]